Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.

@article{Martn2011MotesanibOO,
  title={Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.},
  author={Miguel Angel Mart{\'i}n and Henri Roch{\'e} and Tam{\'a}s Pint{\'e}r and John Crown and Michael J. Kennedy and Louise Provencher and Frank Priou and Wolfgang Eiermann and Encarna Adrover and Istv{\'a}n L{\'a}ng and M. Ramos and J. Phillipe Latreille and Agnieszka Jagiełło-Gruszfeld and Tadeusz Pieńkowski and Emilio Alba and Raymond D Snyder and Sachin Almel and Janusz Rolski and Montserrat Mu{\~n}oz and Rebecca L Moroose and Sara A. Hurvitz and Ana Ba{\~n}os and Henry Adewoye and Yong-jiang Hei and M A Lindsay and Matthieu Rupin and David Cabaribere and Yasmin Lemmerick and John R. Mackey},
  journal={The Lancet. Oncology},
  year={2011},
  volume={12 4},
  pages={369-76}
}
BACKGROUND Vascular endothelial growth factor (VEGF) has a crucial role in angiogenesis, and is a valid target in metastatic breast cancer. Motesanib is an investigational oral inhibitor of VEGF receptors. We aimed to determine whether treatment with motesanib plus paclitaxel is better than placebo plus paclitaxel in patients with HER2-negative locally recurrent or metastatic breast cancer. METHODS Between Dec 1, 2006, and July 4, 2008, patients with untreated HER2-negative metastatic breast… CONTINUE READING
33 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Similar Papers

Loading similar papers…